Background The brain metastasis from differentiated thyroid carcinoma (DTC) is a rare condition and its prognosis is poor. The standard protocol for screening and treatment of patients with brain metastases from papillary thyroid cancer (PTC) remains controversial. This report aims to share the experience of a single center in the management of brain metastases from DTC. Material and methods Five patients with brain metastases were identified from 5000 patients with DTC attending the department of nuclear medicine, Hospital 108 between 2016 to 2022. The statistical software Statistical Package for Social Sciences (SPSS) 20.0 (SPSS Inc., Chicago, IL, USA) was used to analyze the data. Results Five patients with brain metastases from DTC were revealed by MRI, 18F-FDG PET/CT with contrast enhancement, and 131I-SPECT/CT. The median time of overall survival (OS) was 15 months, ranging from 10 to 65 months. Two out of the five patients underwent surgery, and futher 2 patients were treated with stereotactic surgery (SRS). All patients are still alive. Conclusions Brain metastases from DTC are rare. MRI is the preferred imaging mobility to screen brain lesions in DTC. The primary treatment modalities are surgery and SRS.

Background In this study, we investigated the relationship between clinicopathologic factors, BRAFV600E mutation status and [18F] F-fluoro-2-deoxyglucose (FDG) avidity in patients with radioiodine (RAI)-negative recurrent or metastatic differentiated thyroid cancer (DTC). Methods From 2015 to 2018 all patients with suspected recurrent or metastatic radioiodine-negative DTC patients who underwent FDG positron emission tomography/computed tomography (PET/CT) were retrospectively reviewed. Suspected lesions on FDG PET/CT were biopsied and underwent BRAFV600E mutation testing by immunohistochemistry and real-time PCR. Tumor size, recurrent versus metastatic disease, histopathologic features including classical type versus aggressive subtypes (poorly differentiated, tall cell, columnar cell, hobnail variants) and BRAFV600E mutation status were correlated with the SUVmax of highest hypermetabolic lesions on FDG PET/CT by the univariate analysis using logistic regression. Results Sixty-three consecutive patients, 55 (87.3%) female, with median age of 48 (range 17–81) were included. The majority of patients had BRAFV600E mutation and classical subtype, 55/63 (87.3%) and 45/63(71.4%), respectively. Thyroglobulin at the time of suspected recurrence was 262.7 ng/ml (range 16.3–1000) and patients received a median 3 prior RAI treatments. Fifty-four patients (85.7%) had local recurrence. The majority of patients 58/63 (92.1%) had FDG-avid disease on PET/CT. On univariate analysis, tumor size aggressive histopathologic types and distant metastasis are the significant factors for predicting FDG uptake, p = 0.04, p = 0.001 and p = 0.004 respectively. Although FDG uptake of BRAFV600E bearing recurrent/metastatic RAIR DTC lesions was higher than those without the mutation, the difference did not reach statistical significance, SUVmax of 7.11 versus 4.91, respectively, p = 0.2. Conclusion The majority of recurrent or metastatic RAI-negative DTC have BRAFV600E mutation and detectable disease on FDG PET/CT. FDG avidity of the recurrent or metastatic RAI-negative DTC is independently associated with the aggressive histopathologic features.

Objective: To determine the clinicopathologic factors and Ki67 expression predicting triple-negative breast cancer (TNBC). Subject and method: A descriptive study on 169 patients with breast cancer at the 108 Military Central Hospital from October 2015 to September 2020. The status of estrogen receptor (ER), progesteron receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki67 expression were examined by immunochemistry. Result: The mean age of the patients was 53.8 ± 12.2 years. The rate of tumor size larger than 2cm was 54.4% (92/169). The percentage of cases with tumor grade 2 was highest at 64.5% (109/169). The rate of axillary lymph node metastasis was 37.9%. TNBC accounted for 16.6%. The statistically significant correlation was observed between TNBC and location, tumor size, histological grade and Ki67 ≥ 14%. Conclusion: Our study suggested that the right side, histological grade 3 and Ki67 ≥ 14% were independent predictive factor of TNBC.

Objective: The study aims to describe histopathological and immunohistochemistry characteristics in identifying intrahepatic cholangiocarcinoma. Subject and method: A total of 52 patients with intrahepatic cholangiocarcinoma between June 2018 and March 2020 were consecutive in the study. 16G core needle biopsies were implemented for all the patients and ensured the length of the biopsy specimens was at least 1.5cm. All liver specimens were processed according to standard histologic methods with Hematoxylin Eosin (HE) staining, and immunohistochemical staining on an automated Benchmark Ultra machine of Ventana (Roche). Histopathological classification according to The 2019 WHO classification. Result: Most of the intrahepatic cholangiocarcinoma was well-differentiated adenocarcinoma accounted for 40.4%, fibrous connective tissue accounted for 61.5%, and tumor necrosis accounted for only 15.4%. CK19 and CK7 were 100% positive and their expression frequently diffuse. CK20 and Hepar-1 were focal positive expressions for 13.5% and 18.2%, respectively. TTF1 only was positive at 12.5%. Conclusion: Histopathological features and strongly and diffusely positive expression of CK7, CK19, and positive Hepar-1 are very useful immunohistochemistry makers for diagnosis of ICC. However, TTF1 and CK20 also are positive expression at few rates.